| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Medicine and of Biochemistry, Biophysics,and
Genetics, Program in Molecular Biology, Colorado Cancer
Center, University of Colorado Health Sciences Center (J.J.T.,
A.G.-H.), Denver, Colorado 80262,
Wyeth Ayerst Research
(J.R.H.), Princeton, New Jersey 08543
Somatostatin (SRIF) was discovered as an inhibitor of GH secretion from pituitary somatotroph cells. SRIF analogs are very effective agents used to treat neuroendocrine tumors and are now being used with increasing frequency in clinical trials to treat more aggressive malignancies. However, the cellular components mediating SRIF signal transduction remain largely unknown. We have stably overexpressed the SRIF type 2 receptor (SST2) in GH4 rat somatomammotroph cells, establishing a physiologically relevant model system. In this model, the SRIF analog, BIM23014, inhibited forskolin-induced cAMP accumulation, protein kinase A activation, cAMP response element-binding protein phosphorylation, and Pit-1/GHF-1 promoter activation in an okadaic acid-insensitive manner. Pertussis toxin inhibited the effects of BIM23014, documenting that SST2 signaling was coupled to Gi. Moreover, the inhibitory effects of BIM23014 were reversed by overexpression of protein kinase A catalytic subunit, indicating that SRIF does not act via serine/threonine phosphatases, but, rather, by lowering protein kinase A activity. These data define the components of the SRIF/SST2 receptor signaling pathway and provide important mechanistic insights into how SRIF controls neuroendocrine tumors. As SRIF analogs are effective antitumor agents, and many other related compounds are in development, the knowledge gained here will further our understanding of their mechanism of action in other malignancies as well.
This article has been cited by other articles:
 |
|
 |
|
  S. M. Carlton, J. Du, S. Zhou, and R. E. Coggeshall Tonic Control of Peripheral Cutaneous Nociceptors by Somatostatin Receptors J. Neurosci., June 1, 2001; 21(11): 4042 - 4049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Baumeister, M. Wegner, D. Richter, and W. Meyerhof Dual Regulation Of Somatostatin Receptor Subtype 1 Gene Expression By Pit-1 In Anterior Pituitary GH3 Cells Mol. Endocrinol., February 1, 2000; 14(2): 255 - 271. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. D. Kineman, J. Kamegai, and L. A. Frohman Growth Hormone (GH)-Releasing Hormone (GHRH) and the GH Secretagogue (GHS), L692,585, Differentially Modulate Rat Pituitary GHS Receptor and GHRH Receptor Messenger Ribonucleic Acid Levels Endocrinology, August 1, 1999; 140(8): 3581 - 3586. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Obrietan, S. Impey, D. Smith, J. Athos, and D. R. Storm Circadian Regulation of cAMP Response Element-mediated Gene Expression in the Suprachiasmatic Nuclei J. Biol. Chem., June 18, 1999; 274(25): 17748 - 17756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Florio, H. Yao, K. D. Carey, T. J. Dillon, and P. J. S. Stork Somatostatin Activation of Mitogen-Activated Protein Kinase via Somatostatin Receptor 1 (SSTR1) Mol. Endocrinol., January 1, 1999; 13(1): 24 - 37. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. R. Baumbach, T. A. Carrick, M. H. Pausch, B. Bingham, D. Carmignac, I. C. A. F. Robinson, R. Houghten, C. M. Eppler, L. A. Price, and J. R. Zysk A Linear Hexapeptide Somatostatin Antagonist Blocks Somatostatin Activity In Vitro and Influences Growth Hormone Release in Rats Mol. Pharmacol., November 1, 1998; 54(5): 864 - 873. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
